On the public citation graph

Pharmacokinetics and Safety Profile of the Human Anti- Pseudomonas aeruginosa Serotype O11 Immunoglobulin M Monoclonal Antibody KBPA-101 in Healthy Volunteers

https://doi.org/10.1128/aac.01699-08
0 signed · 69 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/jps.20178openalex-snapshot
Antibody Pharmacokinetics and Pharmacodynamics
inferredcites →https://doi.org/10.1007/s00296-006-0183-7openalex-snapshot
Immunogenicity, efficacy and adverse events of adalimumab in RA patients
inferredcites →https://doi.org/10.1016/j.ajic.2003.09.002openalex-snapshot
National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003
inferredcites →https://doi.org/10.1016/j.it.2007.07.011openalex-snapshot
Immunogenicity of protein therapeutics
inferredcites →https://doi.org/10.1016/s0022-3476(95)70158-3openalex-snapshot
Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis
inferredcites →https://doi.org/10.1086/320186openalex-snapshot
Characterization ofPseudomonas aeruginosaIsolates: Occurrence Rates, Antimicrobial Susceptibility Patterns, and Molecular Typing in the Global SENTRY Antimicrobial Surveillance Program, 1997–1999
inferredcites →https://doi.org/10.1086/426189openalex-snapshot
Use of Pharmacokinetics and Pharmacodynamics to Optimize Antimicrobial Treatment of Pseudomonas aeruginosa Infections
inferredcites →https://doi.org/10.1089/hyb.1997.16.413openalex-snapshot
Pharmacokinetics, Tolerability, and Preliminary Efficacy of Human Anti- Pseudomonas aeruginosa Monoclonal Antibodies in Pneumonia and Burn Infection Patients
inferredcites →https://doi.org/10.1093/clinids/6.supplement_3.s617openalex-snapshot
The Virulence of Pseudomonas aeruginosa
inferredcites →https://doi.org/10.1093/infdis/164.4.803openalex-snapshot
Safety, Pharmacokinetics, and Functional Activity of Human Anti-Pseudomonas aeruginosa Monoclonal Antibodies in Septic and Nonseptic Patients
inferredcites →https://doi.org/10.1097/01.cji.0000192105.24583.83openalex-snapshot
Fully Human Therapeutic Monoclonal Antibodies
inferredcites →https://doi.org/10.1097/01.inf.0000129688.50588.acopenalex-snapshot
Vaccination of Cystic Fibrosis Patients Against Pseudomonas aeruginosa Reduces the Proportion of Patients Infected and Delays Time to Infection
inferredcites →https://doi.org/10.1159/000235071openalex-snapshot
Biological Role of Different Antibody Classes
inferredcites →https://doi.org/10.1164/ajrccm/148.3.793openalex-snapshot
The Immunoevasive Activities of Pseudomonas aeruginosa : Relevance for Cystic Fibrosis
inferredcites →https://doi.org/10.1201/ihcdruphasciopenalex-snapshot
Drugs and the Pharmaceutical Sciences
inferredcites →https://doi.org/10.1378/chest.120.6.2059openalex-snapshot
Infection Control in the ICU
inferredcites →https://doi.org/10.3233/hab-1993-4107openalex-snapshot
Pilot study of anti-lipopolysaccharide human monoclonal antibody MAB-T88 in patients with gram-negative sepsis

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.5281/zenodo.1303954openalex-extracted
Immunoprophylaxis Of Pseudomonosis: Achievements And Perspectives
inferred← citeshttps://doi.org/10.1002/9783527682423.ch39openalex-snapshot
In vitro Studies and Clinical Trials about Monoclonal Antibodies Used in Infectiology
inferred← citeshttps://doi.org/10.1007/978-2-8178-0389-0_8openalex-snapshot
Les thérapeutiques infectieuses non antibiotiques
inferred← citeshttps://doi.org/10.1007/978-3-319-48683-3_1openalex-snapshot
Emerging Themes in Drug Resistance
inferred← citeshttps://doi.org/10.1007/s00203-024-04107-zopenalex-snapshot
Respiratory tract infections: an update on the complexity of bacterial diversity, therapeutic interventions and breakthroughs
inferred← citeshttps://doi.org/10.1007/s13546-012-0472-yopenalex-snapshot
Les thérapeutiques anti-infectieuses non antibiotiques
inferred← citeshttps://doi.org/10.1007/s40121-025-01195-2openalex-snapshot
Exploring Human Use of Monoclonal Antibodies Against Critical Bacteria: A Scoping Review of Clinical Trials
inferred← citeshttps://doi.org/10.1007/s40259-026-00787-9openalex-snapshot
Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field
inferred← citeshttps://doi.org/10.1016/j.abb.2012.06.001openalex-snapshot
Anti-bacterial monoclonal antibodies: Back to the future?
inferred← citeshttps://doi.org/10.1016/j.chroma.2010.12.066openalex-snapshot
Chromatographic behavior of IgM:DNA complexes
inferred← citeshttps://doi.org/10.1016/j.drudis.2019.03.002openalex-snapshot
Where are we with monoclonal antibodies for multidrug-resistant infections?
inferred← citeshttps://doi.org/10.1016/j.drup.2011.01.007openalex-snapshot
The global need for effective antibiotics—A summary of plenary presentations
inferred← citeshttps://doi.org/10.1016/j.drup.2011.02.001openalex-snapshot
Fighting bacterial infections—Future treatment options
inferred← citeshttps://doi.org/10.1016/j.drup.2011.02.006openalex-snapshot
The global need for effective antibiotics—Moving towards concerted action
inferred← citeshttps://doi.org/10.1016/j.jchromb.2013.02.004openalex-snapshot
Fast separation of large biomolecules using short monolithic columns
inferred← citeshttps://doi.org/10.1016/j.jpba.2009.11.003openalex-snapshot
A comparative characterization of dipentameric (IgM)2 and pentameric IgM species present in preparations of a monoclonal IgM for therapeutic use
inferred← citeshttps://doi.org/10.1016/j.mehy.2011.06.013openalex-snapshot
Immunoglobulin M as a vaccine adjuvant
inferred← citeshttps://doi.org/10.1016/j.microb.2025.100233openalex-snapshot
Decoding antibiotic resistance in Pseudomonas aeruginosa: Embracing innovative therapies beyond conventional antibiotics
inferred← citeshttps://doi.org/10.1039/d5md00591dopenalex-snapshot
How to spare gut microbiota from antibiotic effects? PK-PD based innovative strategies, target specificity, and molecule-to-medicinal properties
inferred← citeshttps://doi.org/10.1055/a-2500-1878openalex-snapshot
State of the Art and Emerging Technologies in Vaccine Design for Respiratory Pathogens
inferred← citeshttps://doi.org/10.1055/s-0037-1602715openalex-snapshot
New Strategies Targeting Virulence Factors of Staphylococcus aureus and Pseudomonas aeruginosa
inferred← citeshttps://doi.org/10.1080/14728214.2016.1206077openalex-snapshot
Emerging drugs for nosocomial pneumonia
inferred← citeshttps://doi.org/10.1093/burnst/tkae083openalex-snapshot
Understanding the pathophysiology of Pseudomonas aeruginosa colonization as a guide for future treatment for chronic leg ulcers
inferred← citeshttps://doi.org/10.1093/jac/dkr038openalex-snapshot
Anti-Pseudomonas aeruginosa serotype O11 LPS immunoglobulin M monoclonal antibody panobacumab (KBPA101) confers protection in a murine model of acute lung infection
inferred← citeshttps://doi.org/10.1093/jac/dkr046openalex-snapshot
Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia
inferred← citeshttps://doi.org/10.1111/bcp.12096openalex-snapshot
Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe?
inferred← citeshttps://doi.org/10.1128/aac.01142-09openalex-snapshot
PreclinicalIn VitroandIn VivoCharacterization of the Fully Human Monoclonal IgM Antibody KBPA101 Specific forPseudomonas aeruginosaSerotype IATS-O11
inferred← citeshttps://doi.org/10.1128/cmr.00031-19openalex-snapshot
Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections
inferred← citeshttps://doi.org/10.1128/iai.00374-26openalex-snapshot
The interface of biofilm and immune system for Gram-negative ESKAPE pathogens
inferred← citeshttps://doi.org/10.1172/jci.insight.174799openalex-snapshot
Clinical assays rapidly predict bacterial susceptibility to monoclonal antibody therapy
inferred← citeshttps://doi.org/10.1371/journal.pone.0073396openalex-snapshot
The Anti-Pseudomonas aeruginosa Antibody Panobacumab Is Efficacious on Acute Pneumonia in Neutropenic Mice and Has Additive Effects with Meropenem
inferred← citeshttps://doi.org/10.1517/13543784.2016.1168803openalex-snapshot
Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia
inferred← citeshttps://doi.org/10.1586/14760584.2014.890053openalex-snapshot
Vaccines for Pseudomonas aeruginosa : a long and winding road
inferred← citeshttps://doi.org/10.21037/atm.2016.08.63openalex-snapshot
The role of genetics and antibodies in sepsis
inferred← citeshttps://doi.org/10.2147/dddt.s121520openalex-snapshot
Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013
inferred← citeshttps://doi.org/10.2147/idr.s16263openalex-snapshot
Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis
inferred← citeshttps://doi.org/10.2147/idr.s50669openalex-snapshot
Pseudomonas aeruginosa ventilator-associated pneumonia management
inferred← citeshttps://doi.org/10.2174/1389201014666131226143923openalex-snapshot
Current Status of Pseudomonas aeruginosa Vaccine
inferred← citeshttps://doi.org/10.2217/fmb.10.119openalex-snapshot
Postgenomic Strategies in Antibacterial Drug Discovery
inferred← citeshttps://doi.org/10.2217/fmb.14.10openalex-snapshot
Vaccine Development and Passive Immunization for Pseudomonas aeruginosa in Critically ill Patients: A Clinical Update
inferred← citeshttps://doi.org/10.3389/fcimb.2022.926758openalex-snapshot
Virulence Factors of Pseudomonas Aeruginosa and Antivirulence Strategies to Combat Its Drug Resistance
inferred← citeshttps://doi.org/10.3389/fphar.2019.00298openalex-snapshot
Drug Prevention and Control of Ventilator-Associated Pneumonia
inferred← citeshttps://doi.org/10.3389/fphar.2021.673239openalex-snapshot
Targeted Therapeutic Strategies in the Battle Against Pathogenic Bacteria
inferred← citeshttps://doi.org/10.3390/antib7010005openalex-snapshot
Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections
inferred← citeshttps://doi.org/10.3390/antib9040053openalex-snapshot
Structure, Function, and Therapeutic Use of IgM Antibodies
inferred← citeshttps://doi.org/10.3390/ijms262110380openalex-snapshot
EPY001, a Novel Monoclonal Antibody Against Pseudomonas aeruginosa Targeting OprF
inferred← citeshttps://doi.org/10.3390/vaccines10111789openalex-snapshot
Antibody-Based Immunotherapies as a Tool for Tackling Multidrug-Resistant Bacterial Infections
inferred← citeshttps://doi.org/10.3390/vaccines9060670openalex-snapshot
Immunization and Immunotherapy Approaches against Pseudomonas aeruginosa and Burkholderia cepacia Complex Infections
inferred← citeshttps://doi.org/10.4018/978-1-7998-0307-2.ch010openalex-snapshot
Nanomaterials to Overcome Emergence and Re-Emergence of Superbugs
inferred← citeshttps://doi.org/10.4049/jimmunol.1002836openalex-snapshot
IgM Production by Bone Marrow Plasmablasts Contributes to Long-Term Protection against Intracellular Bacterial Infection
inferred← citeshttps://doi.org/10.4155/cli.10.19openalex-snapshot
Strategies to treat sepsis: old and new
inferred← citeshttps://doi.org/10.4161/hv.7.10.16369openalex-snapshot
Recent developments for Pseudomonas vaccines
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.